Department of Surgery, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Sciences, Hiroshima University, Minami-ku, Hiroshima 734-8551, Japan.
Cell Transplant. 2013;22(9):1695-708. doi: 10.3727/096368912X657738. Epub 2012 Oct 8.
Although it is well known that liver allografts are often accepted by recipients, leading to donor-specific tolerance of further organ transplants, the underlying mechanisms remain unclear. We had previously used an in vitro model and showed that mouse liver sinusoidal endothelial cells (LSECs) selectively suppress allospecific T-cells across major histocompatibility complex (MHC) barriers. In the present study, we established an in vivo model for evaluating the immunomodulatory effects of allogeneic LSECs on corresponding T-cells. Allogeneic BALB/cA LSECs were injected intraportally into recombination activating gene 2 γ-chain double-knockout (RAG2/gc-KO, H-2(b)) mice lacking T, B, and natural killer (NK) cells. In order to facilitate LSEC engraftment, the RAG2/gc-KO mice were injected intraperitoneally with monocrotaline 2 days before the adoptive transfer of LSECs; this impaired the host LSECs, conferring a proliferative advantage to the transplanted LSECs. After orthotopic allogeneic LSEC engraftment, the RAG2/gc-KO mice were immune reconstituted intravenously with C57BL/6 splenocytes. After immune reconstitution, mixed lymphocyte reaction (MLR) assay using splenocytes from the recipients revealed that specific inhibition of host CD4(+) and CD8(+) T-cell proliferation was greater in response to allostimulation with irradiated BALB/cA splenocytes rather than to stimulation with irradiated third party SJL/jorllco splenocytes. This inhibitory effect was attenuated by administering anti-programmed death ligand 1 (PD-L1) monoclonal antibody during immune reconstitution in the above-mentioned mice, but not in RAG2/gc-KO mice engrafted with Fas ligand (FasL)-deficient BALB/cA LSECs. Furthermore, engraftment of allogeneic BALB/cA LSECs significantly prolonged the survival of subsequently grafted cognate allogeneic BALB/cA hearts in RAG2/gc-KO mice immune reconstituted with bone marrow transplantation from C57BL/6 mice. In conclusion, murine LSECs have been proven capable of suppressing T-cells with cognate specificity for LSECs in an in vivo model. The programmed death 1/PD-L1 pathway is likely involved in these suppressive effects.
尽管众所周知,肝移植通常会被受者接受,从而导致对进一步器官移植的供体特异性耐受,但潜在机制仍不清楚。我们之前曾使用体外模型表明,小鼠肝窦内皮细胞(LSEC)可选择性地抑制跨越主要组织相容性复合物(MHC)障碍的同种异体 T 细胞。在本研究中,我们建立了一种体内模型,用于评估同种异体 LSEC 对相应 T 细胞的免疫调节作用。将同种异体 BALB/cA LSEC 门静脉内注射到重组激活基因 2 γ链双敲除(RAG2/gc-KO,H-2(b))小鼠中,该小鼠缺乏 T、B 和自然杀伤(NK)细胞。为了促进 LSEC 移植,在同种异体 LSEC 转移前 2 天,RAG2/gc-KO 小鼠腹腔内注射单环酸二钠;这会损害宿主 LSEC,赋予移植的 LSEC 增殖优势。同种异体 LSEC 移植后,RAG2/gc-KO 小鼠静脉内用 C57BL/6 脾细胞进行免疫重建。免疫重建后,用受体脾细胞进行混合淋巴细胞反应(MLR)测定,结果表明,与用照射的第三方 SJL/j 脾细胞刺激相比,对照射的 BALB/cA 脾细胞的同种刺激反应中,宿主 CD4(+)和 CD8(+)T 细胞增殖的特异性抑制更大。在上述小鼠的免疫重建期间给予抗程序性死亡配体 1(PD-L1)单克隆抗体可减弱这种抑制作用,但在移植了 Fas 配体(FasL)缺陷型 BALB/cA LSEC 的 RAG2/gc-KO 小鼠中则不然。此外,同种异体 BALB/cA LSEC 的移植显著延长了在接受 C57BL/6 小鼠骨髓移植免疫重建的 RAG2/gc-KO 小鼠中随后同种异体 BALB/cA 心脏移植的存活时间。总之,在体内模型中,已证明小鼠 LSEC 能够抑制具有 LSEC 同源特异性的 T 细胞。程序性死亡 1/PD-L1 途径可能参与这些抑制作用。